March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Efficacy Of Diquafosol Tetrasodium For Chronic Dry Eye After Laser In Situ Keratomileusis
Author Affiliations & Notes
  • YOSAI MORI
    Miyata Eye Hospital, Miyakonojo, Japan
  • RYOHEI NEJIMA
    Miyata Eye Hospital, Miyakonojo, Japan
  • AYAMI MASUDA
    Miyata Eye Hospital, Miyakonojo, Japan
  • YOKO MARUYAMA
    Miyata Eye Hospital, Miyakonojo, Japan
  • KEIICHIRO MINAMI
    Miyata Eye Hospital, Miyakonojo, Japan
  • KAZUNORI MIYATA
    Miyata Eye Hospital, Miyakonojo, Japan
  • Footnotes
    Commercial Relationships  YOSAI Mori, None; RYOHEI Nejima, None; AYAMI Masuda, None; YOKO Maruyama, None; KEIICHIRO Minami, None; KAZUNORI Miyata, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 574. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      YOSAI MORI, RYOHEI NEJIMA, AYAMI MASUDA, YOKO MARUYAMA, KEIICHIRO MINAMI, KAZUNORI MIYATA; Efficacy Of Diquafosol Tetrasodium For Chronic Dry Eye After Laser In Situ Keratomileusis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):574.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Chronic dry eye is one of major complications after laser in situ keratomileusis (LASIK) and is hard to improve with artificial tear or hyaluronic acid treatment. Diquafosol tetrasodium is P2Y2 receptor agonist stimulating tear fluid and mucin secretion, and would improve ocular surface disorders in dry eye. Aim of the study is to evaluate the efficacy of diquafosol tetrasodium for chronic dry eye after LASIK.

Methods: : This prospective study comprised 30 eyes of 15 patients who had dry eye over 12 months after LASIK with artificial tear or hyaluronic acid treatment. Diquafosol tetrasodium 3% eyedrop was additionally instilled 6 times a day for 12 weeks. Tear secretin was examined with the Schirmer test before and at 4 and 12 weeks after diquafosol treatment. Tear breakup time (BUT), fluorescein stain, and lissamine green stain were examined before and at 1, 4 and 12 weeks. In fluorescein staining on the cornea, area and density were scored in 0 to 3 and the summation was evaluated. Lissamine green staining in the conjunctiva was scored in 0 to 18. Questionnaire of 14 symptoms according to Ocular Surface Disease Index was performed before and at 12 weeks. Change in the examinations after the additional treatment was evaluated with the Friedman's test following Scheffe ad-hoc comparison. Symptoms were compared with the Wilcoxon signed-ranks test.

Results: : Mean tear secretin did not change beween before diquafosol treatment (7.4 mm) and after 4, 12 weeks (7.5, 7.2 mm). BUT significantly increased from before (3.1 sec.) to 1 week (4.6 sec., P<0.001), and continued up to 12 weeks (5.1 sec.). Fluorescein and lissamine green staining scores were also improved from 1 week after the diquafosol treatment (P<0.001). There were significant improvement in 6 symptoms (fatigue, dryness, discomfort, grittiness, reading, dry place).

Conclusions: : Additional instillation of diquafosol tetrasodium 3% improved ocular surface disorder and dry eye symptoms. It was demonstrated that diquafosol tetrasodium facilitated tear fluid and mucin secretion and effectively improved chronic dry eye after LASIK.

Keywords: cornea: tears/tear film/dry eye • cornea: surface mucins 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×